Benitec Biopharma (NASDAQ: BNTC) has developed a breakthrough platform for treating human diseases called DNA-directed RNAi (ddRNAi). Unlike other RNAi-based technologies, ddRNAi effects lasting change in target cells, leading to long term benefits and, potentially, a cure. The company thus holds the dominant global patent position for expressed RNA interference, placing it in a commanding position for human therapies associated with specific genes and genetic disorders. The use of shRNA for use in humans also falls under the company’s patent estate. For more information, visit the company’s website at www.benitec.com.